1 Min Read
Aug 11 (Reuters) - Genmab A/S : * Announces new phase III study of daratumumab in front line multiple myeloma * Says study expected to start in the first half of 2015 Source text for Eikon:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.